Corporate Actions
Material events companies report to the SEC on Form 8-K: mergers, dividends, buybacks, splits, management changes, bankruptcies and more. Enter a ticker for one company's history, or browse the latest across the market.
Fortress Biotech (FBIO)
1 8-K filing| Filed | Action | What the filing says | SEC |
|---|---|---|---|
| Feb 23, 2026 |
Material Agreement
Item 1.01Item 2.03Item 8.01Item 9.01
|
Entry into a Material Definitive Agreement. Priority Review Voucher Asset Purchase Agreement On February 22, 2026, Cyprium Therapeutics, Inc. (“Cyprium”), a majority-owned subsidiary of Fortress Biotech, Inc. (the…Entry into a Material Definitive Agreement. Priority Review Voucher Asset Purchase Agreement On February 22, 2026, Cyprium Therapeutics, Inc. (“Cyprium”), a majority-owned subsidiary of Fortress Biotech, Inc. (the “Company”), entered into a definitive asset purchase agreement (the “PRV APA”) pursuant to which Cyprium agreed to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”). As previously disclosed, the PRV was originally issued in connection with the FDA’s approval of ZYCUBO® (copper histidinate, formerly known as CUTX-101) for the treatment of Menkes disease in pediatric patients and was transferred to Cyprium prior to the entry into the PRV APA. Pursuant to the PRV APA, the buyer agreed to pay Cyprium $205 million, in cash, upon the closing of the sale. The PRV APA contains customary representations, warranties, covenants and indemnification provisions, in each case su |
Filing 8-K |
Each 8-K is classified by its most significant item; hover an item number for its title. Classification and excerpts are read automatically and can be wrong; the filing on SEC.gov is the authority. For research, not investment advice.